Acute lymphoblastic leukaemia (ALL) with the t(4;11) translocation has a very poor prognosis following conventional chemotherapy. Many patients are offered an allogeneic BMT in first remission. We report on the impact of allogeneic BMT on three patients with t(4;11) ALL in first remission. Median age was 20 years. One patient received marrow from an HLA-identical sibling and the other two from unrelated donors. All three engrafted and none of the patients developed acute or chronic GVHD. Remission status was monitored using a sensitive nested RT-PCR to detect the ALL-1/AF-4 hybrid transcript. All three were PCR-negative at 3 months post-BMT. One of the unrelated recipients died of a fungal infection 4 months post-BMT. The other two are alive and in molecular remission at 21 and 24 months post-BMT. This is the first report of longitudinal follow-up of t(4;11) ALL post-allogeneic BMT by PCR. The early attainment of molecular remission in the absence of GVHD suggests that the conditioning regimen may have been more important than a graftversus-leukaemia effect in these patients. Follow-up of larger numbers of patients will be required to confirm these preliminary observations. Keywords: acute lymphoblastic leukaemia; t(4;11); RT-PCR; graft-versus-host disease; graft-versus-leukaemia The t(4;11)(q21;q23) occurs in approximately 5% of adults with acute lymphoblastic leukaemia (ALL). At a molecular level, a reciprocal translocation results in the hybrid transcript ALL-1/AF-4. The mechanism by which this transcript exerts its malignant influence is not known, but it does confer a poor prognosis.
The t(4;11)(q21;q23) occurs in approximately 5% of adults with acute lymphoblastic leukaemia (ALL). At a molecular level, a reciprocal translocation results in the hybrid transcript ALL-1/AF-4. The mechanism by which this transcript exerts its malignant influence is not known, but it does confer a poor prognosis. 1 To this end, many patients with this translocation are offered an allogeneic bone marrow transplant (BMT) in first remission. The value of monitoring minimal residual disease by reverse transcriptase polymerase chain reaction (RT-PCR) has been demonstrated by others. 2 Longitudinal follow-up of affected patients has been previously reported, 3 but not in the setting of BMT.
We now report on the impact of allogeneic BMT in three patients with t(4;11) ALL in first remission. 
Patients and methods
Three female patients with pre-pre-B ALL and t(4;11) were studied. The diagnostic information related to these patients is summarised in Table 1 .
All three patients were entered in the UKALL 12 protocol, and were transplanted in first remission. The donors were HLA-A and -B seromatched and DR␤1 and DQ␤1 molecularly matched.
Two received marrow from unrelated donors. They were cytoreduced with 1440 cGy fractionated TBI (180 cGy × 8) and cyclophosphamide 60 mg/kg/day × 2 and also received CAMPATH-1G 20 mg/day × 5 and thiotepa 5 mg/kg/day × 2 as additional conditioning therapy. The donated marrows were depleted of T cells in vitro using CAMPATH-1M monoclonal antibody plus complement, according to a previously described method. 4 One patient received unmanipulated marrow from an HLA-identical sibling. This patient was conditioned with etoposide 60 mg/kg and 1440 cGy fractionated TBI (180 cGy × 8) and was given cyclosporin A plus methotrexate as GVHD prophylaxis.
Bone marrow samples were obtained at regular intervals for karyotyping and for detection of minimal residual disease by PCR. Total RNA extraction was performed according to the method of Chomczynsky and Sacchi. 5 A sensitive nested RT-PCR according to a previously described method 6 that detects one t(4;11) cell in 10 5 normal cells was used to monitor their bone marrow remission status at regular intervals after induction and transplant (Figure 1 ). Positive and negative controls were run simultaneously. 
Results
All three patients engrafted without evidence of acute or chronic GVHD. One of the unrelated recipients died of a fungal infection 4 months after transplant. The other two are alive and in remission 21 and 24 months after transplant. The longitudinal follow-up of cytogenetic and PCR results are shown in Figure 1 . There were no positive cytogenetic results following BMT. Similarly, the patients remained PCR negative.
Discussion
ALL with the t(4;11) is regarded as one of the worst prognostic groups in both adults and children, with a high rate of relapse after conventional chemotherapy. For this reason, we electively performed allogeneic BMT in our patients in first remission. Whether PCR negativity for the ALL-1/AF-4 hybrid transcript following allogeneic BMT is associated with long-term disease-free survival is not known. All three patients were PCR negative at 3 months post-BMT. This early attainment of molecular remission occurred without any evidence of GVHD. Examination of relapse rates in allogeneic recipients who do or do not develop GVHD is one of the ways to study a possible GVL effect in ALL.
The absence of chronic GVHD after allogeneic BMT has been associated with an increased risk of leukaemia relapse in a multivariate analysis. 6 Similarly, the graft-versus-leukaemia effect of acute and especially chronic GVHD has been confirmed by multivariate analysis. 7 Nevertheless our two survivors have remained PCR negative at 6, 9, 12, 18 and 21 months and the patient with the longest follow-up was PCR negative at 24 months post-BMT. Our data appear to be compatible with the effectiveness of the conditioning regimen in producing a molecular remission in these patients rather than a graft-versus-leukaemia effect. 8 Follow-up of a larger number of patients will be required to confirm these preliminary observations.
